Pegfilgrastim for PBSC mobilization and autologous haematopoietic SCT

A pilot study on the use of outpatient fractionated ifosfamide, carboplatin and etoposide (ICE) and pegfilgrastim as a salvage and mobilizing regimen for relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma

“…[6][7][8][9] However, mobilization of PBSCs using chemotherapy and growth factors is subject to considerable inter-individual variation. In our series, three patients demonstrated very low CD34 þ cell numbers in the peripheral blood and were not leukapheresed.…”

Wiskott-Aldrich syndrome protein-deficient hematopoietic cells can be efficiently mobilized by granulocyte colony-stimulating factor

“…8 There are several mechanisms involved in hematopoietic stem cell mobilization [9][10][11][12] and numerous studies support a major role of the CXCR4/CXCL12 axis in hematopoietic cell retention, trafficking and mobilization. G-CSF potently inhibits osteoblast activity in the bone marrow, reducing CXCL12 expression 13 thereby decreasing retention of cells in the bone marrow and permitting their egress into the periphery.…”

Sources of Hematopoietic Stem Cells

“…Kobbe et al [54] found that in patients with multiple myeloma, a single dose of 6 mg pegfilgrastim after cyclophosphamide (4g/m^2) is equally effective in terms of the mobilization of haematopoietic progenitor cells as daily administration of conventional G-CSF. There is no increase in this effect if the dose is doubled to 12 mg.…”

“…While filgrastim is also cleared by the kidneys, pegfilgrastim is mainly eliminated via a neutrophil-mediated clearance mechanism [52-54]. The initial results of using pegfilgrastim obtained in limited numbers of patients with solid tumours showed that pegylated G-CSF was principally capable of mobilizing haematopoietic progenitor cells [54]. In 2001 and 2003, two studies were designed for the treatment of myeloma patients.…”